Market Overview

UPDATE: Oppenheimer Raises PT on Fidus Investment Corp. on Expected Continued Growth

Share:

In a report published Monday, Oppenheimer reiterated its Outperform rating on Fidus Investment Corp. (NASDAQ: FDUS), and slightly raised its price target from $18.00 to $19.00.

Oppenheimer noted, “Fidus has been the single best-performing business development company in our 18-member BDC tracking group since its June 2011 IPO with a total shareholder return versus the group average of 18%. With that appreciation, the stock is essentially trading at our price target; however, we expect that FDUS will continue to be a good dividend growth story and are expecting a 8.5% dividend yield in 2013 growing to 9.1% in 2014. Thus, in a low rate environment, this is still a good total return, even though some of the lagging BDCs are probably better ‘new money' investments at this juncture.”

Fidus Investment Corp. closed on Friday at $18.83.

Latest Ratings for FDUS

DateFirmActionFromTo
Aug 2019DowngradesBuyNeutral
Jun 2019Initiates Coverage OnBuy
Jan 2017Initiates Coverage OnMarket Perform

View More Analyst Ratings for FDUS
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Price Target Analyst Ratings

 

Related Articles (FDUS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
HSKACanaccord GenuityMaintains75.0
AVGOMorgan StanleyMaintains265.0
AMATNeedhamMaintains56.0
VOYACitigroupMaintains62.0
VCCitigroupMaintains86.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine

UPDATE: Deutsche Bank Raises PT to $6.75 on Resource Capital; Maintains Neutral on Valuation